	Prognostic Value of Enterography Findings in Crohn's Disease: A Systematic Review and Meta-Analysis. J Imaging Montevechi-Luz F, Pansani AHC, Mello JDC, de Paula AEC, Genaro LM, Mazzaro MC, Lahan-Martins D, Leal RF. PMID: 41295109 [PubMed]
	Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy? J Basic Clin Physiol Pharmacol Misra S, Kaur M, Saranjhna AK. PMID: 41292123 [PubMed - as supplied by publisher]
	Explainable ensemble learning for Epstein-Barr virus risk prediction in ulcerative colitis and Crohn's disease using routine biomarkers. Sci Rep Yang Y, Tang X, Chen Y, Yuan H, Hu H, Wang Z, Xiao Y. PMID: 41290898 [PubMed - indexed for MEDLINE]
	Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT. Semin Immunopathol Quiroga-Centeno AC, Atanasova K, Ebert MP, Thomann AK, Reindl W. PMID: 41288714 [PubMed - indexed for MEDLINE]
	Secondary Hemophagocytic Lymphohistiocytosis in a Patient With Crohn's Disease Receiving Infliximab: A Diagnostic Challenge. Cureus Shoukath M, Sobhanan A, Omotosho A, Kanakambujan N, Nandakumar MB, Jamil B. PMID: 41287667 [PubMed]
	Escalation to biologics after corticosteroids in patients with newly diagnosed Crohn's disease in Japan: a claims analysis from 2010 to 2021. Intest Res Matsuura M, Yoon A, Miyoshi J, Hisamatsu T. PMID: 41287515 [PubMed - as supplied by publisher]
	Identification of novel molecular drivers, prognostic and diagnostic biomarkers for Inflammatory Bowel Disease (IBD): protocol for the Nottingham/AstraZeneca prospective IBD observational cohort study. BMJ Open Serna-Valverde AL, Rodriguez-Suarez E, Marks DJB, Gehrmann U, Neisen J, Clarke S, Chew TS, Cummings F, De Silva S, Gordon JN, Knight P, Limdi J, Patel K, Crooks B, Sebastian S, Polytarchou C, Hannan NRF, Moran GW. PMID: 41285507 [PubMed - indexed for MEDLINE]
	Systematic Review and Network Meta-Analysis: Evaluating the Impact of advanced therapies for Moderate-to-Severe Ulcerative Colitis on Health-Related Quality of Life. J Crohns Colitis Katsoula A, Paschos P, Malandris K, Kalogirou MS, Haidich AB, Giouleme O, Tsapas A. PMID: 41284688 [PubMed - as supplied by publisher]
	TRENDS IN THE ULCERATIVE COLITIS TO CROHN'S DISEASE INCIDENCE RATIO ARE DISTINCT BETWEEN EPIDEMIOLOGIC STAGES OF INFLAMMATORY BOWEL DISEASE. Am J Gastroenterol Windsor JW, Coward S, Hracs L, Mak JWY, Banerjee R, Kotze PG, Gearry R, Ng SC, Kaplan GG, Global IBD Visualization of Epidemiology Studies in the 21s,t Century (GIVES-21) Research Group. PMID: 41284467 [PubMed - as supplied by publisher]
	Gut microbiota and metabolic signatures of anxiety in ulcerative colitis: a cross-sectional study. Therap Adv Gastroenterol Ping Y, Zhao X, Lv L, Meng W, Meng Y, Ruan G, Cheng Y, Xiao Z, Tian Y, Chen M, Chen L, Yi A, Tang Z, Li N, Chen D, Wei Y. PMID: 41283171 [PubMed]
	Correction: Identification of shared diagnostic genes between osteoporosis and Crohn's disease through integrated transcriptomic analysis and machine learning. Front Genet Yi G, Zhou P, Yang Q, Zhao M, Yang Q, Li S, Dang C. PMID: 41282481 [PubMed]
	Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North Study. Gastro Hep Adv Nakase H, Fujii T, Hisamatsu T, Suzuki Y, Watanabe M, Takahashi S, Ooi M, Takeuchi K, Kimura T, Furuya K, Aoyama N, Hasatani K, Horiki N, Kanke K, Tokito S, Sai S, Uchikawa Y, Goto S, Fujimoto G, Zhang C, Petersen A, Hibi T. PMID: 41281463 [PubMed]
	Depression and anxiety in inflammatory bowel disease: mechanisms and emerging therapeutics targeting the microbiota-gut-brain axis. Front Immunol Qian Y, Chen Y, Liu L, Wu T, Chen X, Ma G. PMID: 41280932 [PubMed - indexed for MEDLINE]
	Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study. World J Gastroenterol Tzouvala M, Zacharopoulou E, Kalafateli M, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, Karmiris K, Koutroubakis IE, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos K, Christodoulou D, Gaki A, Papathanasiou E, Bamias G, Zampeli E, Michopoulos S, Kyriakos N, Veretanos C, Argyriou K, Kapsoritakis A, Tribonias G, Mantzaris GJ, Liatsos C. PMID: 41278164 [PubMed - indexed for MEDLINE]
	Hydrogen peroxide pathway in ulcerative colitis: Promises and challenges in translating novel pathogenesis to clinical practice. World J Gastroenterol Wang XY, An F, Wang BJ, Han WW. PMID: 41278161 [PubMed - indexed for MEDLINE]
	Research progress concerning the involvement of the intestinal microbiota in the occurrence and development of inflammatory bowel disease. World J Gastroenterol Zheng L, Duan SL, Wang K. PMID: 41278154 [PubMed - indexed for MEDLINE]
	Colonic Tissue Expression of MAdCAM-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease. Clin Transl Sci Reddy N, Klein JA, Thomas N, Micic D, Deng Z, Rubin DT, Cohen RD, Dalal S, Christensen B, Haider HI, Valuckaite V, Meckel KR, Bissonnette M, Weber CR, Pekow J. PMID: 41277578 [PubMed - indexed for MEDLINE]
	Treatment of chronic anal fissure in Crohn's disease patients with freshly collected autologous adipose tissue: a pilot study. Tech Coloproctol Sulaiman A, Dige A, Nordholm AH, Lundby L. PMID: 41275461 [PubMed - as supplied by publisher]
	AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. Gastroenterology Scott FI, Ananthakrishnan AN, Click B, Agrawal M, Syal G, Haydek JP, Yuan Y, Kappelman MD, Lewis JD, Singh S. PMID: 41274746 [PubMed - indexed for MEDLINE]
	Structure-activity relationships of sulfated polysaccharides in inflammatory bowel disease: Sources, mechanisms, and therapeutic potential. Carbohydr Polym Liu W, Shen M, Li J, Xie J. PMID: 41274736 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 55834

Page 1 of 2792



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy